FCR achieves long-term durable remissions in patients with IGHV-mutated CLL

Abstract

In chronic lymphocytic leukemia (CLL) patientswithmutatedIGHV,3recentstudies havedemonstratedprolongedprogression-free survival (PFS) after treatment with fludarabine-cyclophosphamide-rituximab (FCR) chemoimmunotherapy. We performed a systematic review to assess the benefit of FCR for patients with CLL and identified 5 randomized trials that met our inclusion criteria. FCR improved complete remission, PFS and overall survival vs the comparator; median PFS was not reached in the subgroup of CLL patients with mutated IGHV.